中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

16 records (took 0.027 seconds)

    Magnetic separation using nanoparticles
    2.
    发明授权
    Magnetic separation using nanoparticles 有权

    公开(公告)号：US11065356B2

    公开(公告)日：2021-07-20

    申请号：US16511151

    申请日：2019-07-15

    Applicant: Children's Medical Center Corporation ,  Massachusetts Institute of Technology

    Inventor： Jung-Jae Lee ,  Kyung Jae Jeong ,  Daniel S. Kohane

    IPC: A61L9/00 ,  A61L2/00

    Abstract: Nanoparticles as described herein are configured to bind to bacterial contaminants, such as Gram positive bacteria, Gram negative bacteria, and endotoxins. The nanoparticles include a core comprising a magnetic material; and a plurality of ligands attached to the core. The ligands include, for example, bis(dipicolylamine) (“DPA”) coordinated with a metal ion, e.g., Zn2+ or Cu2+, to form, e.g., bis-Zn-DPA or bis-Cu-DPA, which can bind to the bacterial contaminants. The nanoparticles can be included in compositions for use in methods and systems to separate bacterial contaminants from liquids, such as liquids, such as blood, e.g., whole or diluted blood, buffer solutions, albumin solutions, beverages for human and/or animal consumption, e.g., drinking water, liquid medications for humans and/or animals, or other liquids.

    Magnetic separation using nanoparticles
    5.
    发明授权
    Magnetic separation using nanoparticles 有权

    公开(公告)号：US10350320B2

    公开(公告)日：2019-07-16

    申请号：US14167773

    申请日：2014-01-29

    Applicant: Children's Medical Center Corporation ,  Massachusetts Institute of Technology

    Inventor： Jung-Jae Lee ,  Kyung Jae Jeong ,  Daniel S. Kohane

    IPC: A61L9/00 ,  A61L2/00

    Abstract: Nanoparticles as described herein are configured to bind to bacterial contaminants, such as Gram positive bacteria, Gram negative bacteria, and endotoxins. The nanoparticles include a core comprising a magnetic material; and a plurality of ligands attached to the core. The ligands include, for example, bis(dipicolylamine) (“DPA”) coordinated with a metal ion, e.g., Zn2+ or Cu2+, to form, e.g., bis-Zn-DPA or bis-Cu-DPA, which can bind to the bacterial contaminants. The nanoparticles can be included in compositions for use in methods and systems to separate bacterial contaminants from liquids, such as liquids, such as blood, e.g., whole or diluted blood, buffer solutions, albumin solutions, beverages for human and/or animal consumption, e.g., drinking water, liquid medications for humans and/or animals, or other liquids.

    Chemical Permeation Enhancers Enhance Nerve Blockade by Toxins
    7.
    发明申请
    Chemical Permeation Enhancers Enhance Nerve Blockade by Toxins 审中-公开
    化学渗透增强剂增强神经内毒素阻断

    公开(公告)号：US20140080841A1

    公开(公告)日：2014-03-20

    申请号：US14086643

    申请日：2013-11-21

    Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

    Inventor： Daniel S. Kohane ,  Itay Sagie ,  Emmanuel J. Simons

    IPC: A61K47/22 ,  A61K31/445 ,  A61K47/20 ,  A61K47/18 ,  A61K31/519 ,  A61K45/06

    CPC classification number: A61K47/22 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0024 ,  A61K31/445 ,  A61K31/519 ,  A61K45/06 ,  A61K47/18 ,  A61K47/186 ,  A61K47/20 ,  A61K2300/00

    Abstract: Chemical permeation enhancers (CPEs) improve access of local anesthetics to the nerve, thereby improving their performance. Surfactants, representing three CPE sub-groups: anionic, cationic, and nonionic surfactants, were co-injected with tetrodotoxin (TTX) or bupivacaine at the sciatic nerve of Sprague-Dawley rats. All enhancers produced marked concentration-dependent improvements in the frequency and duration of block with TTX but not bupivacaine. An in vitro toxicity assay showed a wide range of CPE myotoxicity, but in vivo histological assessment showed no signs of muscle or nerve damage at concentrations of CPEs that produced a half-maximal increase in the duration of block of TTX. There was no systematic relationship between the enhancers' charge or hydrophobicity and their enhancement of block duration or potency. Thus, CPEs can provide marked prolongation of nerve blockade from TTX, without apparent local tissue toxicity, and therefore enhance the clinical applicability of TTX for prolonged-duration local anesthesia.

    Abstract translation: 化学渗透增强剂（CPE）改善局部麻醉剂对神经的通路，从而改善其性能。 代表三个CPE亚组的表面活性剂：阴离子，阳离子和非离子表面活性剂，与Sprague-Dawley大鼠坐骨神经共同注射河豚毒素（TTX）或布比卡因。 所有增强剂在TTX而不是布比卡因的阻滞频率和持续时间方面产生显着的浓度依赖性改善。 体外毒性测定显示出广泛的CPE肌体毒性，但是在体内组织学评估中，在CPE浓度下，TTX阻滞期持续时间增加最多时，未显示出肌肉或神经损伤的迹象。 增强剂的电荷或疏水性与其阻滞持续时间或效力的增强之间没有系统的关系。 因此，CPE可以从TTX提供显着的神经阻滞延长，没有明显的局部组织毒性，因此提高TTX长期局部麻醉的临床适用性。

    Sensory-Specific Local Anesthesia and Prolonged Duration Local Anesthesia
    10.
    发明申请
    Sensory-Specific Local Anesthesia and Prolonged Duration Local Anesthesia 审中-公开
    感觉特异性局部麻醉和长时间局部麻醉

    公开(公告)号：US20140080913A1

    公开(公告)日：2014-03-20

    申请号：US14086765

    申请日：2013-11-21

    Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

    Inventor： Daniel S. Kohane ,  Itay Sagie

    IPC: A61K47/18 ,  A61K31/167

    CPC classification number: A61K47/18 ,  A61K9/0014 ,  A61K9/0019 ,  A61K31/167

    Abstract: Combinations of charged local anesthetics with chemical permeation enhancers have been developed to give long duration block which is selective for sensory block is greatly prolonged by combining the local anesthetic with a permeation enhancer. The selectivity of sensory over motor block is provided by selecting the concentration of the local anesthetic and the permeation enhancer to provide selective permeability of the sensory and motor neurons to the enhancer.

    Abstract translation: 已经开发了带电的局部麻醉剂与化学渗透促进剂的组合以给予长期阻滞，通过将局部麻醉剂与渗透促进剂组合，可大大延长对感觉阻滞的选择性。 通过选择局部麻醉剂和渗透促进剂的浓度来提供感觉运动阻滞的选择性，以提供感觉运动神经元对增强剂的选择性渗透性。

Patent Agency Ranking